首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1345448

全球凝血分析仪市场 - 2023-2030

Global Coagulation Analyzers Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

全球凝血分析仪市场在 2022 年达到 38 亿美元，预计到 2030 年将达到 61 亿美元，2023-2030 年预测期间复合年增长率为 6.4%。

凝血分析仪是评估和量化血液凝血能力的专用实验室仪器。它们对于诊断和监测与止血和凝血相关的各种医疗状况至关重要，例如出血性疾病、血栓形成和凝血因子缺乏。凝血分析仪可以执行多种测试，包括凝血酶原时间 (PT)、活化部分凝血活酶时间 (aPTT)、国际标准化比值 (INR)、纤维蛋白原水平和 D-二聚体测定等。这些测试提供了有关凝血因子、血小板功能和纤维蛋白溶解的有价值的信息。

此外，慢性血液疾病的患病率不断增加以及凝血分析仪的进步预计将在预测期内推动市场发展。

动力学

Vizient 推进快速床旁凝血分析和创新技术合同预计将推动市场增长

2023 年 8 月 4 日，领先的医疗保健技术公司 HemoSonics 获得了 Vizient 的创新技术合同，实现了一个重要的里程碑。这是一项重大成就，因为 Vizient 代表了美国各地庞大的急症护理医院网络，占美国所有此类医疗机构的一半以上。 HemoSonics 的 Quantra 止血系统是这一成就的基石，代表着尖端医疗技术，有望彻底改变医疗保健环境中的凝血分析。

Quantra 系统包括 Quantra 止血分析仪以及 QPlus 和 QStat 墨盒，为全血凝固分析提供完整的解决方案，所有这些都在护理点交付，并在 15 分钟内产生结果。 HemoSonics 的 Quantra 止血系统是医疗技术不断进步的一个典型例子。通过直接在护理点提供快速、全面的凝血分析，该系统不仅显着提高了诊断能力，而且有可能改善美国各地医院的患者护理和治疗效果。

Vizient 对该系统的认可凸显了其通过提供更高效、更有效的凝血分析方法为医疗保健行业带来积极变化的能力。因此，由于上述因素，预计市场在预测期内将继续增长。

慢性血液疾病患病率的增加预计将推动市场增长

根据世界卫生组织 2023 年报告，贫血是一个重大的公共卫生问题，主要影响幼儿、孕妇和产后妇女以及经期少女和妇女。贫血的最大负担由低收入和中低收入国家承担，特别是那些生活在农村地区、贫困家庭和没有受过正规教育的国家。

统计数据显示，全球范围内，贫血症影响着 40% 的 6-59 个月儿童、37% 的孕妇和 30% 的 15 至 49 岁女性。 2019 年，贫血导致 5000 万年因残疾而丧失健康生命，其中膳食缺铁、地中海贫血镰状细胞性状和疟疾是主要原因。

此外，据估计，全球约有 5 亿 15 至 49 岁的女性以及 2.69 亿 6 至 59 个月大的儿童受到贫血的影响。 2019年，5.39亿非孕妇（约占15岁至49岁女性总数的30%）和3200万孕妇（约占37%）受到贫血影响。

据世界卫生组织称，非洲和东南亚这两个受影响最严重的地区估计有 1.06 亿妇女和 1.03 亿儿童受到贫血症的影响，东南亚有 2.44 亿妇女和 8,300 万名儿童受到贫血症的影响。。因此，由于上述因素，预计市场在预测期内将继续增长。

设备成本高预计将阻碍市场增长

凝血分析仪相当昂贵，SYSMEX CA-560 的平均价格为 1993 美元。这种高昂的成本可能会给诊所或小型实验室等小型医疗机构带来重大的财务障碍。这些设施可能很难拨出很大一部分预算来购买这些分析仪，这可能会限制它们的可访问性。

除了初始购买成本外，凝血分析仪还需要定期维护、校准和使用试剂等消耗品，这会增加医疗机构的预算并造成压力。财务资源有限的小型设施可能不愿意投资需要持续财务承诺的技术。因此，由于上述因素，预计市场在预测期内将受到阻碍。

Overview

Global Coagulation Analyzers Market reached US$ 3.8 billion in 2022 and is expected to reach US$ 6.1 billion by 2030, growing with a CAGR of 6.4% during the forecast period 2023-2030.

Coagulation analyzers are specialized laboratory instruments that evaluate and quantify the blood's clotting ability. They are essential in the diagnosis and monitoring of various medical conditions related to hemostasis and coagulation, such as bleeding disorders, thrombosis, and clotting factor deficiencies. Coagulation analyzers can perform a wide range of tests, including prothrombin time (PT), activated partial thromboplastin time (aPTT), international normalized ratio (INR), fibrinogen levels, and D-dimer assays, among others. These tests provide valuable information about clotting factors, platelet function, and fibrinolysis.

Furthermore, the increasing prevalence of chronic blood disorders and advancement in coagulation analyzers are the factors expected to drive the market over the forecast period.

Dynamics

Advancing Rapid Point-of-Care Coagulation Analysis and Innovative Technology Contract from Vizient is Expected to Drive the Market Growth

On August 4, 2023, HemoSonics, a leading healthcare technology firm, achieved a major milestone by securing an Innovative Technology contract award from Vizient. This is a significant accomplishment since Vizient represents a vast network of acute care hospitals throughout the United States, accounting for more than half of all such healthcare facilities in the country. The Quantra Hemostasis System from HemoSonics is the cornerstone of this achievement, representing cutting-edge medical technology that promises to revolutionize coagulation analysis in healthcare settings.

The Quantra system includes the Quantra Hemostasis Analyzer, as well as the QPlus and QStat cartridges, providing a complete solution for whole-blood coagulation analysis, all delivered at the point of care and yielding results in less than 15 minutes. The Quantra Hemostasis System from HemoSonics is a prime example of the continuous advancement of medical technology. By providing fast and comprehensive coagulation analysis directly at the point of care, the system not only represents a significant improvement in diagnostic capabilities but also holds the potential to enhance patient care and outcomes in hospitals across the United States.

Vizient's recognition of the system highlights its ability to bring about positive changes in the healthcare industry by offering a more efficient and effective approach to coagulation analysis. Hence, owing to the above factors, the market is expected to drive over the forecast period.

Increasing Prevalence of Chronic Blood Disorders is Expected to Drive Market Growth

According to the World Health Organization Report 2023, anemia is a significant public health issue that primarily affects young children, pregnant and postpartum women, and menstruating adolescent girls and women. The greatest burden of anemia is borne by low- and lower-middle-income countries, particularly those living in rural areas, impoverished households, and with no formal education.

Statistics indicate that globally, anemia affects 40% of all children aged 6-59 months, 37% of pregnant women, and 30% of women aged between 15 and 49 years. In 2019, anemia caused 50 million years of healthy life loss due to disability, with dietary iron deficiency, thalassemia sickle cell trait, and malaria being the leading causes.

Furthermore, it is estimated that around 500 million women between the ages of 15 and 49, as well as 269 million children aged between 6 and 59 months, are affected by anemia worldwide. In 2019, 539 million non-pregnant women, which is around 30% of all women aged between 15 and 49, and 32 million pregnant women, which is around 37%, were affected by anemia.

The two most affected regions, Africa and South-East Asia, have an estimated 106 million women and 103 million children affected by anemia in Africa, and 244 million women and 83 million children affected in South-East Asia, according to the World Health Organization. Hence, owing to the above factors, the market is expected to drive over the forecast period.

High Cost of Equipment is Expected to Hamper the Market Growth

Coagulation analyzers are quite expensive, with the SYSMEX CA-560 costing an average of $1993. This high cost can pose a significant financial obstacle for smaller healthcare facilities like clinics or smaller laboratories. These facilities may struggle to set aside a large portion of their budget to purchase these analyzers, which may limit their accessibility.

Apart from the initial purchase cost, coagulation analyzers also require regular maintenance, calibration, and the use of consumables such as reagents, which can add up and strain the budgets of healthcare facilities. Smaller facilities with limited financial resources may be reluctant to invest in technology that requires ongoing financial commitments. Hence, owing to the above factors, the market is expected to hamper over the forecast period.

Segment Analysis

The global coagulation analyzers market is segmented based on product type, test type, technology, end-user and region.

The D-Dimer Testing from the Test Type Segment Accounted for Approximately 43.7% of the Coagulation Analyzers Market Share

D-dimer testing is an essential part of coagulation analysis that enables healthcare professionals to assess whether there is an abnormal blood clot formation in the body. D-dimer is a protein fragment produced when fibrin, another protein involved in blood clot formation, breaks down. Elevated levels of D-dimer in the blood can indicate the presence of an active blood clotting process, which makes it a valuable diagnostic tool in various medical situations.

For instance, when a blood clot travels to the lungs and blocks a pulmonary artery, it results in Pulmonary Embolism (PE). In this case, D-Dimer testing is frequently used alongside other diagnostic techniques, such as computed tomography pulmonary angiography (CTPA), to assess the possibility of PE. Increased D-Dimer levels may necessitate additional imaging to confirm the diagnosis.

Furthermore, the rising incidence of thrombotic disorders, the growing aging population, advancements in analytical technologies, and the development of point-of-care D-Dimer testing devices are the factors expected to drive the market segment over the forecast period. For instance, in October 2021, Trivitron Healthcare collaborated with Diagon Ltd to release a range of Coagulation Analyzer products, which includes systems for coagulation testing and D-Dimer testing capabilities.

The launch of these new products provides healthcare providers with a wider range of options, which could lead to an increase in the adoption of D-Dimer testing. This launch is a significant advancement in the field of coagulation analysis, especially for D-Dimer testing. The introduction of new and innovative products with improved accuracy and scalability is expected to drive the adoption of D-Dimer testing in clinical and patient management across various healthcare settings in India. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period

Geographical Penetration

North America Accounted for Approximately 39.6% of the Market Share in 2022, Owing to the Increasing Prevalence of Chronic Blood Disorders, and the Launch of Coagulation Analyzers

North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of chronic blood disorders, and the launch of coagulation analyzers.

For instance, Siemens Healthineers showcased their commitment as a trusted partner in hemostasis testing at the 31st Congress of the International Society on Thrombosis and Haemostasis in Montreal, Canada, from June 24 to 28, 2023. They invited attendees to join them at ISTH 2024 in Bangkok, Thailand, where they plan to showcase their coagulation testing portfolio for the first time in Asia.

During the event, Siemens Healthineers placed their focus on their Coagulation Analyzers, which cater to the needs of various laboratories. They highlighted technological advancements aimed at streamlining hemostasis testing processes as well as introducing the CN-3000 and CN-6000 Hemostasis Systems, stressing their connectivity options, compact size, intelligent software, and high throughput.

Siemens Healthineers also discussed their scalable coagulation analyzer portfolio, which includes the CN-3000 and CN-6000 Systems, the CS-2500 System (a mid-volume automated solution), and the CS-5100 System (a high-volume automated solution). The company emphasized the advantages of automation in coagulation testing and shared customer success stories from Finland and Switzerland where automation enhanced their testing processes.

Furthermore, during the presentation, Siemens Healthineers highlighted the importance of digitalization in hemostasis testing. They introduced their Atellica Diagnostics IT solutions, which can help laboratories improve efficiency and patient care. Additionally, they discussed the potential of AI in predicting coagulation disorders and provided a downloadable poster on this topic.

Siemens Healthineers also emphasized their commitment to providing coagulation assays that aid physicians in making accurate diagnostic and therapeutic decisions. This commitment is particularly important in cases of von Willebrand disease (VWD) with a focus on improving patient outcomes.

They showcased their CN-3000 and CN-6000 Hemostasis Systems, which are their smallest, fastest, smartest, and most flexible hemostasis analyzers yet. These analyzers have intelligent software and connectivity options, making them suitable for laboratories with different testing volumes and needs. Hence, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the coagulation analyzers market include: Roche Diagnostics, Siemens Healthineers AG, Helena Laboratories Corporation, Meril Life Sciences Pvt. Ltd., Trivitron Healthcare, Sysmex Asia Pacific Pte Ltd, A&T Corp, Genrui Biotech Inc., ERBA Diagnostics, Inc., and Maccura Biotechnology Co. Ltd among others.

COVID-19 Impact Analysis

The coagulation analyzers market has positively impacted by the COVID-19 pandemic. These medical devices are crucial in assessing a person's blood clotting ability, which is necessary for diagnosing and managing various medical conditions, including bleeding disorders and thrombosis. Due to the pandemic, there was an increased demand for coagulation testing as COVID-19 patients were often found to have coagulation abnormalities, including a higher risk of blood clots. Healthcare facilities and hospitals require more coagulation analyzers to effectively monitor and manage these patients.

Moreover, due to the increasing demand and the need to reduce the burden on central laboratories, there has been a noticeable trend towards the use of point-of-care devices for coagulation testing. These portable analyzers have made bedside testing more convenient and faster, leading to quicker treatment decisions by healthcare providers. The pandemic has led to more research on coagulation abnormalities associated with COVID-19, resulting in the development of new assays and technologies that improve the accuracy and diagnostic capabilities of coagulation analyzers.

By Product Type

Analyzers
- Clinical Laboratory Analyzers
- Point of Care Analyzers

Consumables
Reagents

By Test Type

Prothrombin Time (PT)
Activated Partial Thromboplastin Time (aPTT)
D-Dimer Testing
Fibrinogen Testing
Others

By Technology

Optical Technology
Mechanical Technology
Electrochemical Technology

By End User

Hospitals
Clinical Laboratories
Research Institutes
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

On May 9, 2022, Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, launched its new CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities. The announcement was made at the World Federation of Hemophilia Congress taking place in Montreal, May 8-11, 2022.
On February 9, 2021, Siemens Healthineers and Sysmex Corporation announced the renewal of the company's long-standing global supply, distributorship, sales, and service agreement for a broad portfolio of hemostasis products including a multi-year extension. Additionally, the company agreement includes the future distribution of Sysmex's CN-Series automated blood coagulation analyzers, the CN-3000 and CN-6000, by Siemens Healthineers bringing the next generation of fully-automated solutions for mid-and high-volume coagulation testing to laboratories. The companies plan for Siemens Healthineers to start commercialization of the Sysmex CN Systems in various countries later this year.
On October 20, 2021, Trivitron Healthcare, a leading medical devices company announced the launch of a new line of Coagulation Analyzer products manufactured by Diagon Ltd. Trivitron in partnership with Diagon-Vanguard Diagnostics India announced the introduction of these products for the Indian Diagnostics Market following the signing of a collaboration agreement between the companies. This launch augurs well for the medical fraternity as it enhances the efficacies in clinical decision-making and broadens patient management. The new products include the COAG Line automated, semi-automated, and POC systems manufactured by Diagon Hungary for reducing bleeding risk in extensive surgeries and checking the efficacy of haemostatic therapies and anti-coagulant drugs.

Why Purchase the Report?

To visualize the global coagulation analyzers market segmentation based on product type, test type, technology, end user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of coagulation analyzers market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global coagulation analyzers market report would provide approximately 69 tables, 70 figures, and 186 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Test Type
3.3. Snippet by Technology
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Potential Treatment for Diabetic Neuropathic Pain
  - 4.1.1.2. Increasing Prevalence of Chronic Blood Disorders
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of Equipment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Patent Analysis
5.7. Russian-Ukraine Conflict Analysis
5.8. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Analyzers*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Clinical Laboratory Analyzers
- 7.2.4. Point of Care Analyzers
7.3. Consumables
7.4. Reagents

8. By Test Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 8.1.2. Market Attractiveness Index, By Test Type
8.2. Prothrombin Time (PT)*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Activated Partial Thromboplastin Time (aPTT)
8.4. D-Dimer Testing
8.5. Fibrinogen Testing
8.6. Others

9. By Technology

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.1.2. Market Attractiveness Index, By Technology
9.2. Optical Technology*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Mechanical Technology
9.4. Electrochemical Technology

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Clinical Laboratories
10.4. Research Institutes
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Tye
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Roche Diagnostics*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Siemens Healthineers AG
13.3. Helena Laboratories Corporation
13.4. Meril Life Sciences Pvt. Ltd.
13.5. Trivitron Healthcare
13.6. Sysmex Asia Pacific Pte Ltd
13.7. A&T Corp
13.8. Genrui Biotech Inc.
13.9. ERBA Diagnostics, Inc.
13.10. Maccura Biotechnology Co. Ltd

LIST NOT EXHAUSTIVE